

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria Virginia 22313-1450

APPLICATION	NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/656,360 09/05/2003		09/05/2003	Mitsunori Ono	09808-017002	7835
26161	7590	03/16/2005		EXAMINER	
	RICHARI		BALASUBRAMANIAN, VENKATARAMAN		
BOSTON, MA 02110				ART UNIT	PAPER NUMBER
				1624	

DATE MAILED: 03/16/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/656,360	ONO ET AL.				
		Examiner	Art Unit				
		Venkataraman Balasubramanian	1624				
Period fo	The MAILING DATE of this communication apport Reply	pears on the cover sheet with the c	orrespondence address				
THE - Exte after - If the - If NC - Failt Any	ORTENED STATUTORY PERIOD FOR REPL' MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period of ure to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be timey within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed on 20 D	ecember 2004.	•				
•		action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5)⊠ 6)⊠ 7)□	Claim(s) 47 and 49-100 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  Claim(s) 55-100 is/are allowed.  Claim(s) 47 and 49-54 is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or election requirement.						
Applicat	ion Papers						
·	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct	epted or b) objected to by the liderawing(s) be held in abeyance. See	e 37 CFR 1.85(a).	<b>,</b>			
11)	The oath or declaration is objected to by the Ex		•	<i>)</i> .			
Priority (	under 35 U.S.C. § 119						
а)	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  Certified copies of the priority document  Certified copies of the priority document  Copies of the certified copies of the priority document  application from the International Bureau  See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachmen	t(s)						
1) Notic	e of References Cited (PTO-892)	4) Interview Summary					
3) 🔲 Infor	ee of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate atent Application (PTO-152)				

Art Unit: 1624

## **DETAILED ACTION**

Applicants' response, which included cancellation of claim 48, amendment to claim 47 and addition of new claims 49-100, filed on 12/20/2004, is made of record.

Claims 47 and 49-100 are now pending.

## Specification

Specification under cross references to related applications need to amended to indicate the applications 10/006,624 and 09/594,362 are now US Patents 6,680,315 and 6,384,032 respectively.

In view of applicants' amendment to claim 47, the 112 first paragraph rejection made in the previous office action has been obviated.

However the following rejections apply.

## **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Application/Control Number: 10/656,360

Art Unit: 1624

•

Claims 47 and 49-54 are rejected under the judicially created doctrine of

Patent No. 6,384,032. Although the conflicting claims are not identical, they are not

obviousness-type double patenting as being unpatentable over claims 26-34 of U.S.

patentably distinct from each other because the same method of uses claimed in the

instant claims are also generically claimed in the claims 26-34 of US 6,384,034.

. Instant method of use claims 47 and 49-54 are rejected over mode of action

claims 26-34 of US 6,384,034, as mode of action relates to treatment of the diseases. In

this regard applicants attention to drawn to the court decision, wherein the court held

that double Patenting applies between a mode of action and the treatment of disease if

one of ordinary skill in the art would know of the connection between the two. See Lilly

vs. Barr, 58 USPQ2d 1869, at 1879.

Allowable Subject Matter

Claims 55-100 would be allowable as prior art search in the relevant art area did

not teach or suggest the pharmaceutical composition embraced in the claims 55-100.

Conclusion

Any inquiry concerning this communication from the examiner should be

addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571)

272-0662. The examiner can normally be reached on Monday through Thursday from

8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is

Mukund Shah whose telephone number is (571) 272-0674. If Applicants are unable to

reach Mukund Shah within 24-hour period, they may contact James O. Wilson, Acting-

SPE of art unit 1624 at 571-272-0661. The fax phone number for the organization

Application/Control Number: 10/656,360

Art Unit: 1624

where this application or proceeding is assigned (703) 872-9306. Any inquiry of a

Page 4

general nature or relating to the status of this application or proceeding should be

directed to the receptionist whose telephone number is (571) 272-1600.

Venkataraman Balasubamanan Venkataraman Balasubramanian

3/12/2005